Message from VistaGen CEO regarding operations as we navigate COVID-19  Read Letter

Looking beyond current treatments for CNS diseases and disorders with high unmet need

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medications for anxiety, depression and other central nervous system, or “CNS,” diseases and disorders where current treatments are inadequate to address high unmet need. Our CNS portfolio includes three differentiated CNS drug candidates, PH94B, PH10 and AV-101, each with a novel mechanism of action, an exceptional safety profile, and therapeutic potential for multiple indications.

Our CNS Pipeline

Going Beyond Current Treatment Options for Depression and Social Anxiety Disorder

Learn more about our CNS Pipeline

Experienced Leadership

Our experienced leadership team has a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Nasdaq: VTGN Symbol
Day Range
52 Week Range

Email Updates

Be the first to receive news, events & updates Sign Up